What happened with ZLAB today?
No read yet
Uses news and trading volume to explain the day’s move and how it relates to the market.
Stop guessing. Get the call, a three-month target price, the best and worst cases, and a source for every claim.
Zai Lab brings treatments for cancer, immune disorders and infectious diseases to patients in Greater China. Almost all revenue comes from product sales, mainly in mainland China, with ZEJULA for ovarian cancer and the VYVGART franchise together contributing most. Distributors buy products from Zai Lab and resell them to healthcare providers; its sales teams work with major medical centers to encourage adoption. A small group of distributors accounts for a substantial share of sales, with the largest customer alone contributing a meaningful portion.
Most products and development candidates are licensed from other drug companies. Zai Lab pays those partners upfront fees, milestone payments and royalties on sales. Its commercial portfolio depends on keeping territorial rights, including ZEJULA rights from Tesaro/GSK and VYVGART rights from argenx. Several products also depend on partner supply: argenx, for example, supplies VYVGART. Alongside licensed programs, Zai Lab conducts its own drug discovery and development.
Sales depend on physician and patient acceptance, reliable supply and affordable access. Inclusion in mainland China's national drug reimbursement list can broaden access but requires negotiated price reductions. Zai Lab may sell products only where regulators have approved them, and only for approved indications; its research pipeline does not yet have those permissions.
The risk section is the longest, dullest part of the filing. This keeps only what can really hurt you: where it hits, how hard, when it plays out.
Every company claims an edge. Each one is checked against hard numbers like margins and returns: which hold, and which line gives way first.
Beyond this list, Zai Lab depends on Paratek’s successor owners for NUZYRA rights, Deciphera for QINLOCK supply and MediLink’s licensed technology for its global DLL3-targeting antibody-drug conjugate program.
Zai Lab depends on argenx for both the Greater China rights and exclusive supply of efgartigimod, which it sells as VYVGART. argenx receives royalties and sales-based milestone payments from those sales, making its Greater China royalty revenue a direct window into VYVGART uptake.
Zai Lab’s largest commercial product, the ovarian cancer medicine ZEJULA, relies on GSK’s license for mainland China, Hong Kong and Macau. GSK also supplies ZEJULA for Hong Kong, but Zai Lab is not otherwise obliged to buy it from GSK—a narrower supply dependence than the licensing tie.
Zai Lab relies exclusively on NovoCure Limited for Optune cancer-treatment devices sold in Greater China, and the two jointly develop the electric-field treatment, called TTFields, for additional solid tumors. NovoCure’s active-patient numbers and new-indication results are worth watching for clues to treatment uptake and Optune’s expansion potential.
AstraZeneca competes for the same ovarian cancer treatment market in China: its Lynparza rivals Zai Lab’s ZEJULA.
Zai Lab’s fast-growing XACDURO antibiotic depends entirely on Innoviva, Inc. for supply, and supply limits have partly constrained rising patient demand and hospital adoption. Watch Innoviva’s XACDURO sales outside the United States: their 2025 increase mainly came from supplies billed to Zai Lab at cost, rather than Zai Lab’s final product sales.
HUTCHMED and Zai Lab both sell innovative cancer medicines in China, so reimbursement coverage and hospital uptake matter to both businesses. Watch HUTCHMED’s Elunate sales following its January 2026 reimbursement renewal and added endometrial cancer coverage for a read on how coverage translates into cancer-drug demand.
BeOne Medicines and Zai Lab both run China-based innovative cancer-medicine businesses, leaving both exposed to Chinese reimbursement policy and clinical-development outcomes.
Amgen’s approved Imdelltra gives Zai Lab’s Phase 3 DLL3-targeting candidate an established treatment to beat in small-cell lung cancer. Imdelltra recruits immune cells to attack cancer, while Zai Lab’s candidate uses an antibody to deliver a drug payload; watch Imdelltra’s clinical performance as a benchmark for differentiation.
IDEAYA Biosciences, Inc.’s IDE849 competes with Zai Lab’s Phase 3 ZL-1310 in developing treatments that target DLL3. Watch IDE849’s efficacy and safety results alongside ZL-1310’s relapsed small-cell lung cancer trial to judge how Zai Lab’s antibody-delivered drug payload compares.
Zai Lab depends on Bristol Myers Squibb as its exclusive supplier of AUGTYRO; BMS also owns Karuna, whose agreement gives Zai Lab rights to develop, manufacture and sell KarXT in Greater China.
Ascentage Pharma and Zai Lab both sell innovative cancer medicines in China whose uptake depends on national reimbursement coverage and hospital access. Ascentage’s Olverembatinib sales after all its commercialized indications gained reimbursement in January 2025 offer a concrete check on how broader coverage supports uptake.
AstraZeneca PLC earningsAZN
AstraZeneca’s report will show how Lynparza is faring in China’s ovarian-cancer market, where it competes with Zai Lab’s ZEJULA.
Look for AstraZeneca’s disclosure on Lynparza sales or demand and compare it with ZEJULA’s reported hospital sales in China. Stronger Lynparza demand would show a rival continuing to attract patients, making it harder for ZEJULA to defend its use in hospitals; weaker demand could ease competitive pressure, but would not establish that patients shifted to ZEJULA. The conclusion is whether competition facing ZEJULA is intensifying, not how ZEJULA itself sold.
Zai Lab Limited earningsThis company
Zai Lab’s report will show whether hospital adoption is translating into product revenue after rebates, enough to support its continued research and selling costs.
Read net product revenue alongside rebates and returns, and check whether growth extends beyond one product. If sales of products such as XACDURO and NUZYRA expand and net revenue follows, hospital adoption is producing revenue the company keeps. If revenue growth slows or rebates and returns absorb more of sales, demand is not yet translating fully into retained revenue. Since Zai Lab continues to lose money, the conclusion is whether product revenue is increasingly covering research and commercialization costs.
